FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesGDPR Considerations for DtP Supply Chains
Topics: Regulatory, Supply Chain
Guidance Document
Free
Video on ACE Requirements
Topics: Pharma Industry, Strategic Planning
Video
Members
Recent Developments in the Global Regulatory Landscape
Topic: Regulatory
Webinar
Free
